Rifaximin-Alpha and Other Crystalline Forms of Rifaximin: Are There Any Differences?
https://doi.org/10.37489/0235-2990-2020-65-7-8-52-62
Abstract
Rifaximin is an antibiotic characterized by polymorphism. It has various crystalline forms with different pharmacological characteristics. Rifaximin acts locally in the digestive tract, therefore it is important for the absorption to be minimal and for concentration in the intestinal lumen to be high. The absorption of other crystalline forms of rifaximin in the intestine is greater than that of rifaximin-α (Alpha Normix®). Differences in pharmacokinetics of the crystalline forms of rifaximin may affect its effectiveness and safety, especially in patients with chronic diseases (immunodeficiency and leaky gut against the background of liver cirrhosis) who require long courses of therapy. Rifaximin-α (Alpha Normix®) is unique as it has eubiotic and anti-inflammatory properties in addition to local antibacterial effect. Given its diverse mechanisms of action, rifaximin-α positively modulates gut microbiota.
About the Authors
S. K. Zyryanov
RUDN University
Russian Federation
Moscow
Russian Federation
Moscow
E. A. Baybulatova
RUDN University
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Huang L.F., Tong W.Q. Impact of solid state properties on developability assessment of drug candidates. Adv Drug Delivery Rev 2004; 56 (3): 321–334. doi: 10.1016/j.addr.2003.10.007.
2. Marchi E., Montecchi L. Imidazo-rifamycin derivatives with antimicrobial utility US Patent, 1982 No. 4,341,785.
3. Jiang Z.D., Ke S., Palazzini E., Riopel L., Dupont H. In vitro activity and fecal concentration of rifaximin after oral administration, Antimicrob Agents Chemother 2000; 44: 2205–2206. doi: 10.1128/aac.44.8.2205-2206.2000.
4. Hoover W.W., Hugh Gerlach E., Hoban D.J. et al. Antimicrobial activity and spectrum of Rifaximin, a new topical Rifamycin derivative. Diagn Microbiol Infect Dis 1993; 16 (2): 111–118. doi: 10.1016/0732-8893(93)90004-q.
5. Jiang Z.D., DuPont H.L. Rifaximin: in vitro and in vivo antibacterial activity. A review, Chemotherapy 2005; 51 (Suppl 1): 67–72. doi: 10.1159/000081991.
6. Ericsson C.D., DuPont H.L. Rifaximin in the treatment of infectious diarrhea, Chemotherapy 2005; 51 (Suppl 1): 73–80. doi: 10.1159/000081992.
7. Baker D.E. Rifaximin: a nonabsorbed oral antibiotic. Rev Gastroenterol Disord 2005; 5 (1): 19–30.
8. Lamanna A., Orsi A. In vitro activity of rifaximin and rifampicin against some anaerobic bacteria, Chemioterapia 1984; 3 (6): 365–367.
9. Descombe J.J., Dubourg D., Picard M., Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994; 14 (2): 51–56.
10. Taylor D.N., Bourgeois A.L., Ericsson C.D. et al. A randomized, doubleblind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Amer J Trop Med 2006; 74: 1060–1066.
11. Grant D.J.W. Theory and origin of polymorphism. In: Brittain HG, editor. Polymorphism in pharmaceutical solids. New York: Marcel Dekker; 1999; 1–34.
12. Rodriguez-Spong B., Price C.P., Jayasankar A., Matzger A.J., Rodriguez- Hornedo N. General principles of pharmaceutical solid polymorphism: a supramolecular perspective. Adv Drug Deliv Rev 2004; 56: 241–274.
13. Viscomi G.C., Campana M., Barbanti M., Grepioni F., Polito M., Confortini D. et al. Crystal forms of rifaximin and their effect on pharmaceutical properties. Cryst Eng Comm 2008; 10: 1074–1081.
14. Scarpignato C., Barbara G., Lanas L. et al. Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017. Ther Adv Gastroenterol 2018; 11: 1–21. doi: 10.1177/1756284818771305.
15. Noeske J., Nkamsse P.N. Impact of resistance to antituberculosis drugs on treatment outcome using World Health Organization standard regimens. Trans R Soc Trop Med Hyg 2002; 96 (4): 429–433.
16. Senol G., Komurcuoglu B., Komurcuoglu A. Drug resistance of Mycobacterium tuberculosis in Western Turkey: a retrospective study from 1100-bed teaching hospital. J Infect 2005; 50 (4): 306–311.
17. Instruktsiya po meditsinskomu primenenijyu preparata AL''FA NORMIKS®. Data obrashcheniya: 14.04.2020. [in Russian]
18. Eksperimental'naya i klinicheskaya farmakologiya selektivnogo kishechnogo antibiotika rifaksimina. Pediatricheskaya Farmakologiya 2008; 5 (3): 120–128. [in Russian]
19. Blandizzi C. et al. Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers. Pharmacol Res 2014; http://dx.doi.org/10.1016/j.phrs.2014.05.001.
20. Soro O., Pesce A., Raggi M., Debbia F.A., Schito G.C. Selection of rifampicin-resistant Mycobacterium tuberculosis does not occur in the presence of low concentration of rifaximin. Clin Microbiol Infect 1997; 3: 147–151.
21. Novoa-Farias O., Frati-Munari A.C., Peredo M.A., Flores-Juarez S., Novoa-Garcia O., Galicia-Tapia J. et al. Susceptibility to rifaximin and other antimicrobial agents of bacteria isolated from acute gastrointestinal infections in Mexico. Rev Gastroenterol Mex 2016; 81: 3–10.
22. Gatta L., Scarpignato C. Systematic review with metaanalysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 2017; 45: 604–616.
23. Latella G., Pimpo M.T., Sottili S., Zippi M., Viscido A., Chiara- monte M. et al. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 2003;18: 55–62.
24. Brigidi P., Swennen E., Rizzello F., Bozzolasco M., Matteuzzi D. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother 2002 Jun; 14 (3): 290–295. doi: 10.1179/joc.2002.14.3.290.
25. Calanni F., Renzulli C., Barbanti M., Viscomi G.C. Rifaximin: beyond the traditional antibiotic activity. J Antibiot (Tokyo) 2014 Sep; 67 (9): 667–670. doi: 10.1038/ja.2014.106.
26. Fiorucci S., Distrutti E., Mencarelli A. et al. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion 2002; 66 (4): 246–256. doi: 10.1159/000068362.
27. Bajaj J.S., Hylemon P.B., Ridlon J.M. et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 2012; 303 (6): 675–685.
28. Bellot P., France´s R., Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int 20`3; 33 (1): 31–39.
29. Miele L., Valenza V., La Torre G. et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49 (6): 1877–1887.
30. Brown J.A. et al. Pre-steady state kinetic analysis of the incorporation of anti-HIV nucleotide analogs catalyzed by human X- and Y-family DNA polymerases. Antimicrob Agents Chemother Nov 2010. DOI: 10.1128/AAC.01229-10.
31. Brown E.L., Xue Q., Jiang Z.D., Xu Y., Dupont H.L. Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrob Agents Chemother 2010; 54 (1): 388–396. doi:10.1128/AAC.00691-09
32. Ponziani F.R., Scaldaferri F., Petito V. The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. Dig Dis 2016; 34 (3): 269–278. doi: 10.1159/000443361.
33. Soldi S., Vasileiadis S., Uggeri F. et al. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clin Exp Gastroenterol 2015; 8: 309–325.
34. Maccaferri S., Vitali B., Klinder A. et al. Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother 2010; 65 (12): 2556–2565. doi:10.1093/jac/dkq345
35. Bajaj J. S. et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS ONE 2013; 8: e60042. https://doi.org/10.1371/journal.pone.0060042
36. Kalambokis G. N. et al. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin Gastroenterol Hepatol 2012; 10: 815–818.
37. Kakiyama G. et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013; 58 (5): 949–955. doi:10.1016/j.jhep.2013.01.003
38. Xu. D. et al. Rifaximin alters intestinal bacteria and prevents stressinduced gut inflammation and visceral hyperalgesia in rats. Gastroenterology 2014; 146 (2): 484–496.e4. doi:10.1053/j.gastro.2013.10.026
39. Cianci R. et al. Scand J Gastroenterol. 2009; 44: 108–115.
40. Cuomo R., Barbara G., Annibale B. Rifaximin and diverticular disease: position paper of the Italian Society of Gastroenterology (SIGE). Dig Liver Dis 2017; 49: 595–603.
41. Cheng J., Shah Y. M., Gonzalez F. J. Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends Pharmacol Sci 2012; 33 (6): 323–330. doi:10.1016/j.tips.2012.03.003
42. Mencarelli A. et al. Inhibition of NF-kappaB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. Eur J Pharmacol 2011; 668 (1–2): 317–324. doi:10.1016/j.ejphar.2011.06.058.
43. Cheng J. et al. Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther 2010; 335 (1): 32–41. doi:10.1124/jpet.110.170225
44. Terc J., Hansen A., Alston L., Hirota S. A. Pregnane X receptor agonists enhance intestinal epithelial wound healing and repair of the intestinal barrier following the induction of experimental colitis. Eur J Pharm Sci 2014; 55: 12–19. doi:10.1016/j.ejps.2014.01.007
45. Jiang Z. D., Ke S., DuPont H. L. Rifaximin-induced alteration of virulence of diarrhea-producing Escherichia coli and Shigella sonnei. Int J Antimicrob Agents 2010; 35 (3): 278–281. doi: 10.1016/j.ijantimicag.2009.11.013.
46. Debbia E.A., Maioli E., Roveta S., Marchese A. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. J Chemother 2008; 20 (2): 186–194. doi:10.1179/joc.2008.20.2.186.
47. Shayto R.H., Mrad R.A,, Sharara A.I. Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol 2016 Aug 7; 22 (29): 6638–6651. doi: 10.3748/wjg.v22.i29.6638.
48. Kyoung Sup Hong. Rifaximin for the treatment of acute infectious diarrheaTherap Adv Gastroenterol 2011 Jul; 4 (4): 227–235. doi: 10.1177/1756283X11398734.
49. Gomi H., Jiang Z.-D., Adacghi J.A. et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. Antimicrob Agents Chemother 1991; 45: 212–216.
50. DuPont H.L., Jiang Z.D., Belkind-Garson J. et al. Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol 2007; 5: 451–456.
51. DuPont H.L., Jiang Z.D., Ericsson C.D. et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001; 33: 1807–1815.
52. DuPont H.L., Haake R., Taylor D.N. et al. Rifaximine treatment of pathogen-negative travelers' diarrhea. J Travel Med 2007; 14: 16–19.
53. Taylor D.N., Bourgeois A.L., Ericsson C.D. et al. A randomized, doubleblind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med 2006; 74: 1060–1066.
54. Steffen R., Sack D.A., Riopel L. et al. Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol 2003; 98: 1073–1078.
55. Zanger P., Nurjadi D., Gabor J. et al. Effectiveness of rifaximin in prevention of diarrhea in individuals travelling to south and southeast Asia: a randomized, doible-blind, placebo-controlled, phase 3 trial. Lancet Infect Dis 2013; 13: 946–954.
56. Hu Y., Ren J., Zhan M. et al. Efficacy of rifaximin in prevention of travelers; diarrhea: a meta-analysis of randomized, double-blind, placebocontrolled trials. J Travel Med 2012; 19: 352–356.
57. Flamm S.L., Mullen K.D., Heimanson Z., Sanyal A.J. Rifaximin has the potential to prevent complications of cirrhosis. Therap Adv Gastroenterol 2018; 11: 1756284818800307. doi: 10.1177/1756284818800307.
58. Kang S.H. et al. Alimentary Pharmacology & Therapeutics 2017; 46: 9: 845–855.
59. Bajaj J.S., Heuman D.M., Sanyal A.J. et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 2013; 8: e60042.
60. Di Piazza S., Gabriella F.M., Valenza L.M. et al. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol 1991; 23: 403–407.
61. Pedretti G., Calzetti C., Missale G., Fiaccadori F. Rifaximin versus neomycin on hyperammonemia in chronic portal systemic encephalopathy of cirrhotics: a double-blind, randomized trial. Ital J Gastroenterol 1991; 23: 175–178.
62. Bucci L., Palmieri G.C. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993; 13: 109–118.
63. Mas A., Rodes J., Sunyer L. et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind,double-dummy, controlled clinical trial. J Hepatol 2003; 38: 51–58.
64. Mullen K.D., Sanyal A., Bass N.M., Poordad F.,Sheikh M.Y., Frederick R.T. et al. Long-term Safety and Efficacy of Rifaximin for the Maintenance of Remission from Overt Hepatic Encephalopathy in Patients wtih Cirrhosis (submitted). Submitted. 2013.
65. Shayto R.H., Mrad R.A,, Sharara A.I. Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol 2016 Aug 7; 22 (29): 6638–6651. doi: 10.3748/wjg.v22.i29.6638.
66. Pimentel M., Lembo A., Chey W.D. et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. New Engl J Med 2011; 364: 22–32.
67. Maev I.V., Cheremushkin S.V., Kucheryavyj Jyu.A., Cheremushkina N.V. Farmakoterapiya sindroma razdrazhennogo kishechnika s pozitsij dokazatel'noj meditsiny. Terapevticheskij Arkhiv 2015; 2: 4–10. doi: 10.17116/terarkh20158724-10. [in Russian]
68. Drossman D.A., Corazziari E., Delvaux M., Spiller R., Talley N.J., Thompson W.G. et al. Rome III: The Functional Gastrointestinal Disorders. 3rd ed. McLean, VA: Degnon Associates, 2006; 30.
69. Dupont H.L., Jiang Z.D., Ericsson C.D. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001; 33 (ll): 1807–1815.
70. Lakshmi C.P., Ghoshal U.C., Kumar S., Goel A., Misra A., Mohindra S. et al. Frequency andfactors associated with small intestinal bacterial overgrowth in patients with cirrhosis of the liver and extra hepatic portal venous obstruction. Dig Dis Sci 2010; 55: 1142–1148.
71. Lauritano E.C., Gabrielli M., Scarpellini E. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci 2009; 13 (2): 111–116.
72. Agafonova N.A. Nevsasyvajyushchiesya (kishechnye) antibakterial'nye preparaty v gastroenterologii: spektr primeneniya rifaksimina. Consilium medicum. Gastroenterologiya 2009; 1: 61–66. [in Russian]
73. Gasbarrini A., Lauritano E.C., Gabrielli M. Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis 2007; 25 (3): 237–240.
74. Peralta S., Cottone C., Doveri T. et al. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin. World J Gastroenterol 2009; 5 (21): 2628–2631.
75. Scarpellini E., Gabrielli M., Lauritano C.E. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2007; 25 (7): 781–786.
76. Saadi M., McCallum R.W. Rifaximin in irritable bowel syndrome: rationale, evidence and clinical use. Ther Adv Chronic Dis 2013; 4 (2): 71–75. doi: 10.1177/2040622312472008.
77. Pimentel M., Cash B.D., Lembo A. et al. Repeat rifaximin for irritable bowel syndrome: no clinically significant changes in stool microbial antibiotic sensitivity. Dig Dis Sci 2017; 62: 2455–2463.
78. Shayto R.H., Mrad R.A,, Sharara A.I. Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol 2016 Aug 7; 22 (29): 6638–6651. doi: 10.3748/wjg.v22.i29.6638.
79. Lechenie divertikulyarnoj bolezni kishechnika v tret'em tysyacheletii: Osnovnye tezisy simpoziuma, sostoyavshegosya v ramkakh Ob#edinennoj evropejskoj gastroenterologicheskoj nedeli 2017. [in Russian]
80. Gatta L., Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 2017; 45: 604–616.
81. Barbara G., Scaioli E., Barbaro M.R. et al. Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease. Gut 2017; 66: 1252–1261.
82. Annibale B., Lahner E., Maconi G. et al. Clinical features of symptomatic uncomplicated diverticular disease: a multicenter Italian survey. Int J Colorectal Dis 2012; 27: 1151–1159.
83. Frieri G., Pimpo M.T., Scarpignato C. Management of colonic diverticular disease. Digestion 2006; 73 (Suppl. 1): 58–66.
84. Cuomo R., Barbara G., Pace F. et al. Italian consensus conference for colonic diverticulosis and diverticular disease. United European Gastroenterol J 2014; 2: 413–442.
85. Binda G.A., Cuomo R., Laghi A. et al. Practice parameters for the treatment of colonic diverticular disease: Italian Society of Colon and Rectal Surgery (SICCR) guidelines. Tech Coloproctol 2015; 19: 615–626.
86. Scarpignato C. Ther Adv Gastroenterol 2018; 11: 1–21 doi: 10.1177/1756284818771305.
87. Shayto R.H., Mrad R.A., Sharara A.I. Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol. 2016 Aug 7; 22 (29): 6638–6651. doi: 10.3748/wjg.v22.i29.6638.
88. Maccaferri S., Vitali B., Klinder A. et al. Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother 2010; 65: 2556–2565.
89. Scarpignato С. Rifaximin, a Poorly Absorbed Antibiotic: Pharmacology and Clinical Use. Karger Medical and Scientific Publishers. 2005; 51.
90. Moroz N., Sitarz R., Mruk A. et al.The use of rifaximin in pre-operative period of patients with tumors of the gastrointestinal tract — a retrospective study (2013–2016). Pol Przegl Chir 2018; 28; 90 (1): 35–40. doi: 10.5604/01.3001.0011.5958.
91. Bedenkov A.V., Bazarov A.S., Strachunskij L.S. i dr. Rutinnaya praktika perioperatsionnogo naznacheniya antibiotikov pri abdominal'nykh operatsiyakh v Rossii: rezul'- taty mnogotsentrovogo issledovaniya. Klinicheskaya Mikrobiologiya i Antimikrobnaya Terapiya 2003; 5: 12: 234–241. [in Russian]
92. Golub A.V., Kozlov R.S. Antibiotikoprofilaktika v kolorektal'noj khirurgii. Klinicheskaya Mikrobiologiya i Antimikrobnaya Terapiya 2007; 9: 3: 244–252. [in Russian]
93. Pleshkov V.G., Golub A.V., Bedenkov A.V. i dr. Rutinnaya praktika perioperatsionnogo naznacheniya antibiotikov v khirurgicheskikh statsionarakh Smolenskoj oblasti. Infektsii v Khirurgii 2004; 2: 18: 24. [in Russian]
94. RKI-Ratgeber Infektionskrankheiten — Merkblatter fur Arzte: Clostridium difficile. Epid Bull 2009; 24: 234–239.
95. Zabikhova A.G., Abelevich A.I. Profilaktika posleoperatsionnykh gnojno-septicheskikh oslozhnenij i C. difficile-assotsiirovannogo kolita v kolorektal'noj khirurgii. Meditsinskij Al'manakh 2013; 5 (29): 126–129. [in Russian]
Review
For citations:
Zyryanov S.K., Baybulatova E.A. Rifaximin-Alpha and Other Crystalline Forms of Rifaximin: Are There Any Differences? Antibiot Khimioter = Antibiotics and Chemotherapy. 2020;65(7-8):52-62. (In Russ.) https://doi.org/10.37489/0235-2990-2020-65-7-8-52-62
Views:
13890
Email this article 